Prothrombotic changes in patients with COVID-19 are associated with disease severity and mortality.

ABSTRACT:

Background and aims

Patients with severe coronavirus disease 2019 (COVID-19) are at significant risk of thrombotic complications. However, their prothrombotic state is incompletely understood. Therefore, we measured in vivo activation markers of hemostasis, plasma levels of hemostatic proteins, and functional assays of coagulation and fibrinolysis in plasma from patients with COVID-19 and determined their association with disease severity and 30-day mortality.

Methods

We included 102 patients with COVID-19 receiving various levels of respiratory support admitted to general wards, intermediate units, or intensive care units and collected plasma samples shortly after hospital admission.

Results

Patients with COVID-19 with higher respiratory support had increased in vivo

SUBMITTER: von Meijenfeldt FA 

PROVIDER: S-EPMC7845083 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature